Tema Trading & Prediction Markets ETF DICE
21.38 USD -0.13 (-0.61%)
At closeNov 13, 2026, 4:15 PM EST
21.38 0.00 0.00%
After hours · Nov 13, 4:15 PM ET
21.37 Day range 21.38
21.15 52-week range 26.16
- YTD
- -15.02%
- 1 year
- -15.02%
News
etftrends.com Novel ETFs: New Milestones for Crypto, Leverage, & Sports ETF issuers continue to push the boundaries of product innovation and unconventional strategies attract greater attention, as regulators consider the next wave of novel ETFs outlined in my previous…
benzinga.com Anthropic, Kalshi and Polymarket Before Their IPOs? ETFs Are Finding a Way in Tema ETFs is offering pre-IPO exposure to Anthropic, Kalshi and Polymarket through ETFs, using SPVs to access private-market names.
etftrends.com Novel ETFs: New Strategies Push Boundaries As ETF strategies continue to expand into new asset classes and structures, the SEC has been taking a closer look at how some of these products fit within existing regulations.
prnewswire.com Lilly Completes Acquisition of DICE Therapeutics INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition…
prnewswire.com Lilly Announces Extension of Tender Offer to Acquire DICE INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares…
marketwatch.com Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts…
businesswire.com DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023 
zacks.com DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.
zacks.com ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline,…
proactiveinvestors.com Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in a…
fool.com Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event? Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal.
businesswire.com DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023 
fool.com Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag.
benzinga.com Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
gurufocus.com Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice…
benzinga.com Dow Dips Over 300 Points; DICE Therapeutics Shares Spike Higher U.S. stocks traded lower midway through trading, with Dow Jones dropping over 300 points on Tuesday. The Dow traded down 0.96% to 33,969.42 while the NASDAQ fell 0.74% to 13,588.13. The S&P 500, also…
investopedia.com Eli Lilly Buys DICE Therapeutics for $2.4 Billion Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close.
investopedia.com Markets Fall at Midday, Pulled Lower by Energy Stocks Markets opened the shortened trading week on Tuesday, June 20, 2023 with losses as oil stocks sank along with the price of crude.
fool.com Why Shares of Dice Therapeutics Are Skyrocketing Tuesday Lilly is paying a 40% premium for Dice's shares. Dice is a clinical-stage biotech with six programs in its pipeline.
stockmarket.com 2 Biotech Stocks For Your June 2023 Watchlist Biotech stocks to watch in the stock market now.
schaeffersresearch.com Options Traders Blast Dice Therapeutics Stock After Buyout Dice Therapeutics Inc (NASDAQ:DICE) was last seen up 37.6% to trade at a fresh all-time high of $46.56, after Eli Lilly (LLY) revealed it will buy the immunology drug maker for roughly $2.4 billion ,…
investorplace.com Why Is Dice Therapeutics (DICE) Stock Up 38% Today? Dice Therapeutics (NASDAQ: DICE ) stock is surging higher on Tuesday after Eli Lilly (NYSE: LLY ) announced plans to acquire the biopharmaceutical company. According to a news release, Eli Lilly is…
proactiveinvestors.com Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover Eli Lilly and Co (NYSE:LLY) said it has signed a definitive agreement to acquire DICE Therapeutics for $2.4 billion, sending shares of the biopharmaceutical company higher in pre-market trade. Under…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 - benzinga.com Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022 Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low…- benzinga.com Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 951 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's morning trading, 400 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
benzinga.com 48 Biggest Movers From Yesterday Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares surged 98.4% to settle at $18.87 on Wednesday on above-average volume. The company on Tuesday disclosed the resignation of its CEO and Chairman and…- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021 Upgrades
- benzinga.com 36 Biggest Movers From Yesterday Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares climbed 36.4% to settle at $10.35 on Tuesday amid an increase in the price of Bitcoin and Ethereum.
benzinga.com 35 Stocks Moving In Monday's Mid-Day Session Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday.- benzinga.com 53 Biggest Movers From Yesterday Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.